Results 1 to 10 of about 3,164,975 (245)
Feasibility of anti-HCV reflex HCV Ag screening strategy in an HCV endemic community
Journal of the Formosan Medical Association, 2021 Background/Purpose: The HCV core antigen (HCV Ag) assay displays high sensitivity and strong correlation with HCV RNA. However, the feasibility of anti-HCV reflex HCV Ag screening in a community-wide setting is rarely discussed.
Wei-Ming Chen +6 more
doaj +4 more sources
Acta Pharmaceutica Sinica B, 2016 Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A protein.
Xing-quan Zhang
openaire +4 more sources
Open Forum Infectious Diseases, 2019 Our study aims to estimate the burden of hepatitis C virus (HCV) infection among the general population in Mainland China. We searched 4 databases for studies of the prevalence of anti-HCV antibody among the general population.
Siyan Zhan, Feng Sun, Yuhua Gao
exaly +2 more sources
Anti-HCV drugs in the pipeline [PDF]
Current Opinion in Virology, 2011 Several directly acting and host targeting antivirals that inhibit hepatitis C virus replication have entered clinical trials. Among the most advanced of these are RG7128, an inhibitor of the NS5B polymerase; BMS-790052, an inhibitor of NS5A; and alisporivir, an inhibitor of human cyclophilins. These agents have potent antiviral activity in chronic HCV
Priscilla L, Yang +4 more
openaire +3 more sources
Anti-HCV prevalence in the general population of Lithuania [PDF]
Medical Science Monitor, 2012 The aim of this study was to assess risk factors for HCV acquisition and prevalence of anti-HCV in the general population of Lithuania.The study enrolled 1528 randomly selected adults from the 5 biggest cities of Lithuania and its rural regions.
Liakina, Valentina, Valantinas, Jonas
openaire +4 more sources
Recent advances in the anti-HCV mechanisms of interferon
Acta Pharmaceutica Sinica B, 2014 Interferon (IFN) in combination with ribavirin has been the standard of care (SOC) for chronic hepatitis C for the past few decades. Although the current SOC lacks the desired efficacy, and 4 new direct-acting antiviral agents have been recently approved, interferons are still likely to remain the cornerstone of therapy for some time.
Menghao Huang +2 more
openaire +4 more sources
The diagnostic significance of hepatitis C virus antibody levels for chronic hepatitis C virus infection [PDF]
The Korean Journal of Internal Medicine, 2023 Background/Aims Although anti-hepatitis C virus (HCV) assay is widely used to screen for HCV infection, it has a high false-positive (FP) rate in low-risk populations.
Jin Gu Kang +10 more
doaj +1 more source
Journal of Antimicrobial Chemotherapy, 2021 Background Current approaches of drug repurposing against COVID-19 have not proven overwhelmingly successful and the SARS-CoV-2 pandemic continues to cause major global mortality.
Carolina Q. Sacramento +39 more
semanticscholar +1 more source
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Life Science, 2020 Aims A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries.
Abdo A. Elfiky
semanticscholar +1 more source